C:\Program Files\Stnexp\Queries\09399083 (amd 2).str






```
chain nodes :
    10  12
ring nodes :
    1  2  3  4  5  6  7  8  9
chain bonds :
    1-10  7-12
ring bonds :
    1-2  1-6  2-3  2-7  3-4  3-9  4-5  5-6  7-8  8-9
exact/norm bonds :
    1-10  3-9  7-12  8-9
exact bonds :
    2-7  7-8
normalized bonds :
    1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
    containing 1 :


Match level :
    1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS  12:Atom
Generic attributes :
    12:
    Saturation              : Unsaturated
    Number of Carbon Atoms : less than 7
    Type of Ring System     : Monocyclic

Element Count :
    Node 12: Limited
        C,C5
```

=>
Uploading C:\Program Files\Stnexp\Queries\09399083 (amd).str



chain nodes :
10 11 13 15 16 17 20 21 22 23 24 27 28 29 30 31 32 33 34 35 36
37 38 39 46 47 48 62
ring nodes :
1 2 3 4 5 6 7 8 9 42 43 44 45
chain bonds :
1-10 5-11 7-13 13-62 15-16 16-39 17-39 20-21 21-22 21-23 23-24 27-28
28-29 30-31 30-32 32-33 34-35 35-36 35-37 37-38 44-46 46-47 47-48

```
ring bonds :
1-2  1-6  2-3  2-7  3-4  3-9  4-5  5-6  7-8  8-9  42-43  42-45  43-44  44-45
exact/norm bonds :
1-10  3-9  7-13  8-9  13-62  15-16  16-39  17-39  20-21  21-22  21-23  23-24  27-28
 28-29  30-31  30-32  32-33  34-35  35-36  35-37  37-38  42-43  42-45  43-44  44-45
 44-46  47-48
exact bonds :
2-7  5-11  7-8  46-47
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 : 42 :


G1:[*1],[*2],[*3],[*4],[*5],[*6]

Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
11:CLASS  13:Atom  15:CLASS  16:CLASS  17:Atom  20:CLASS  21:CLASS  22:CLASS
23:CLASS  24:CLASS  27:CLASS  28:CLASS  29:CLASS  30:CLASS  31:CLASS  32:CLASS
33:CLASS  34:CLASS  35:CLASS  36:CLASS  37:CLASS  38:CLASS  39:CLASS  42:Atom
43:Atom  44:Atom  45:Atom  46:CLASS  47:CLASS  48:Atom  62:CLASS
Generic attributes :
13:
Saturation              : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System     : Monocyclic

Element Count :
Node 13: Limited
    C,C5




L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 17:05:31 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1178 TO ITERATE

100.0% PROCESSED     1178 ITERATIONS                              0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
```

PROJECTED ITERATIONS: 21501 TO 25619
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=>
Uploading C:\Program Files\Stnexp\Queries\09399083 (amd 1).str



chain nodes :
10 11 13
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-10 5-11 7-13
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
exact/norm bonds :
1-10 3-9 7-13 8-9
exact bonds :
2-7 5-11 7-8
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 13:Atom
Generic attributes :
13:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

Element Count :
Node 13: Limited
C,C5

L3 STRUCTURE UPLOADED

```
=> d l3
L3 HAS NO ANSWERS
L3                STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l3 sss sam
SAMPLE SEARCH INITIATED 17:06:36 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1179 TO ITERATE

100.0% PROCESSED     1179 ITERATIONS                                 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         21521 TO    25639
PROJECTED ANSWERS:                3 TO      163

L4             3 SEA SSS SAM L3

=> =>
Uploading C:\Program Files\Stnexp\Queries\09399083 (amd 2).str
```



```
chain nodes :
10  12
ring nodes :
1  2  3  4  5  6  7  8  9
chain bonds :
1-10  7-12
ring bonds :
1-2  1-6  2-3  2-7  3-4  3-9  4-5  5-6  7-8  8-9
```

```
exact/norm bonds :
1-10  3-9  7-12  8-9
exact bonds :
2-7  7-8
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6
isolated ring systems :
containing 1 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:CLASS
12:Atom
Generic attributes :
12:
Saturation              : Unsaturated
Number of Carbon Atoms  : less than 7
Type of Ring System     : Monocyclic

Element Count :
Node 12: Limited
    C,C5




L5      STRUCTURE UPLOADED

=> d l5
L5 HAS NO ANSWERS
L5              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l5 sss sam
SAMPLE SEARCH INITIATED 17:07:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     1179 TO ITERATE

100.0% PROCESSED     1179 ITERATIONS                                 3 ANSWERS
SEARCH TIME: 00.00.01
```

```
FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        21521 TO    25639
PROJECTED ANSWERS:               3 TO      163

L6            3 SEA SSS SAM L5

=> s l5 sss ful
FULL SEARCH INITIATED 17:08:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -    24730 TO ITERATE

100.0% PROCESSED    24730 ITERATIONS                                 35 ANSWERS
SEARCH TIME: 00.00.01

L7           35 SEA SSS FUL L5

=> => s l7
L8            8 L7

=> d l8 1-8 bib,ab,hitstr
```

L8 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2007:1146415 CAPLUS
DN 147:440294
TI Novel cyclobutyl compounds as kinase inhibitors for cancer treatment
IN Heinrich, Timo; Staehle, Wolfgang; Greiner, Hartmut; Blaukat, Andree
PA Merck Patent G.m.b.H., Germany
SO Ger. Offen., 45pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 102006016426	A1	20071011	DE 2006-102006016426	20060407
AU 2007236361	A1	20071018	AU 2007-236361	20070308
CA 2647690	A1	20071018	CA 2007-2647690	20070308
WO 2007115620	A2	20071018	WO 2007-EP1993	20070308
WO 2007115620	A3	20071129		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 2004651	A2	20081224	EP 2007-711852	20070308

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR

PRAI DE 2006-102006016426 A 20060407
WO 2007-EP1993 W 20070308
OS MARPAT 147:440294
AB The invention concerns the preparation and use of cyclobutyl compds. of the general formula (I), where R1, R2' and R2" are defined; the cyclobutyl compds. are used for the treatment of tumors and diseases the cause of which is related to protein kinases.
IT 952029-90-2 952029-92-4 952029-94-6
952029-97-9 952029-99-1
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synthesis of cyclobutyl compds. as kinase inhibitors for cancer treatment)
RN 952029-90-2 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
5-(2-furanyl)-7-[3-(1-pyrrolidinylmethyl)cyclobutyl]- (CA INDEX NAME)



RN 952029-92-4 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
5-(3-furanyl)-7-[3-(1-pyrrolidinylmethyl)cyclobutyl]- (CA INDEX NAME)



RN 952029-94-6 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
7-[3-(1-pyrrolidinylmethyl)cyclobutyl]-5-(3-thienyl)- (CA INDEX NAME)



RN 952029-97-9 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
5-(4-pyridinyl)-7-[3-(1-pyrrolidinylmethyl)cyclobutyl]- (CA INDEX NAME)



RN 952029-99-1 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
5-(3-pyridinyl)-7-[3-(1-pyrrolidinylmethyl)cyclobutyl]- (CA INDEX NAME)



L8 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:892793 CAPLUS
DN 139:365176
TI Preparation of nucleoside derivatives for treating hepatitis C virus infection
IN Roberts, Christopher Don; Dyatkina, Natalia B.; Keicher, Jesse D.; Liehr, Sebastian Johannes Reinhard; Hanson, Eric Jason
PA Genelabs Technologies, Inc., USA
SO PCT Int. Appl., 182 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003093290	A2	20031113	WO 2003-US14237	20030506
	WO 2003093290	A3	20040318		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2484921	A1	20031113	CA 2003-2484921	20030506
	AU 2003232071	A1	20031117	AU 2003-232071	20030506
	US 20040063658	A1	20040401	US 2003-431631	20030506
	EP 1501850	A2	20050202	EP 2003-747674	20030506
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	BR 2003009581	A	20050329	BR 2003-9581	20030506
	CN 1653077	A	20050810	CN 2003-810239	20030506
	JP 2005530759	T	20051013	JP 2004-501429	20030506
	NZ 536123	A	20060929	NZ 2003-536123	20030506
	ZA 2004008588	A	20070328	ZA 2004-8588	20030506
	MX 2004010983	A	20050214	MX 2004-10983	20041105
	NO 2004005247	A	20041130	NO 2004-5247	20041130
PRAI	US 2002-378624P	P	20020506		
	US 2002-392871P	P	20020628		
	WO 2003-US14237	W	20030506		

OS MARPAT 139:365176
AB Nucleosides I-III, wherein R and R1 are independently H, alkyl, alkenyl, alkynyl, provided that R and R1 are not both H; R2 is alkyl, cycloalkyl, alkenyl, alkynyl, acylamino, guanidino, amidino, thioacylamino, OH, alkoxy, halo, nitro, aryl, heteroaryl, substituted amine; W is H, phosphate, phosphonate, acyl, alkyl, sulfonate, lipid, amino acid, sugar residue, peptide, cholesterol; X is H, halo, alkyl, substituted amine; Y is H, halo, OH, alkylthio, substituted amine; Z is H, halo, OH, alkyl, substituted amine; T is nucleobase, were prepared as HCV RNA polymerase inhibitors and for treating hepatitis C virus infections. Thus, 2-(4-amino-pyrrolo[3,2-c]pyridin-1-yl)-5-hydroxymethyl-3-methyltetrahydro-furan-3,4-diol was prepared for treating hepatitis C virus infections (no data). Different kind of formulation such as tablet, capsule, suspension, injectable, and suppository formulation are reported.

IT 622381-06-0P 622381-08-2P
RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of nucleoside derivs. for treating hepatitis C virus infection)
RN 622381-06-0 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(2-furanyl)-7-β-D-ribofuranosyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 622381-08-2 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(2-oxazolyl)-7-β-D-ribofuranosyl- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:777394 CAPLUS
DN 139:292260
TI Preparation of 4-aminopyrrolopyrimidines as protein kinase inhibitors
IN Calderwood, David; Arnold, Lee; Mazdiyasni, Hormoz; Hirst, Gavin C.; Deng, Bojuan B.; Johnston, David N.; Rafferty, Paul; Tometzki, Gerald B.; Twigger, Helen L.; Munschauer, Rainer
PA USA
SO U.S. Pat. Appl. Publ., 93 pp., Cont.-in-part of U.S. 6,001,839.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 20030187001	A1	20031002	US 1999-399083	19990917
US 6001839	A	19991214	US 1998-42702	19980317
PRAI US 1998-42702	A2	19980317		
US 1998-100954P	P	19980918		

OS MARPAT 139:292260
AB 7H-Pyrrolo[2,3-d]pyrimidin-4-amines [I; A = (un)substituted 6-membered aromatic ring or 5- or 6-membered heteroarom. ring; L = RbNRSO2, RbNRP(O), or RbNRP(O)O, where Rb = alkylene group which when taken together with the sulfonamide, phosphinamide or phosphonamide group to which it is bound forms a 5- or 6-membered ring fused to ring A, or L = O, S, NR, 5-7 membered (oxa)azaphosphaarom. or (oxa)azaphosphacycloalkyl ring, or a variety of linkers containing functional groups; R = H, acyl, or (un)substituted aliphatic, (hetero)aromatic, or cycloalkyl; R1 = H, 2-Ph-1,3-dioxan-5-yl or (un)substituted (cyclo)alkyl, cycloalkenyl, or phenylalkyl; R2 = H, halo, OH, CN, (un)substituted aliphatic, cycloalkyl, (hetero)aromatic, (hetero)aralkyl, amino, or amido; R3 = (un)substituted aliphatic, alkenyl, (hetero)cycloalkyl, or (hetero)aromatic; n = 0-6], and physiol. acceptable salts and metabolites thereof, were prepared For example, II was prepared in a 6-step sequence involving: (1) amine protection of 4-bromo-2-methoxyaniline with di-tert-Bu dicarbonate, (2) 4-addition of diboron pinacol ester, (3) 4-substitution with 4-chloro-7-cyclopentyl-5-iodo-7H-pyrrolo[2,3-d]pyrimidine, (4) deprotection of the amine with F3CCO2H, (5) 4-amination of the pyrrolopyrimidine, and (6) amidation of the aniline with 4-cyanobenzenesulfonyl chloride. I inhibit serine/threonine and tyrosine kinase activity, affecting immunol., hyperproliferative, and angiogenic processes. All exemplified compds. significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at concns. of ≤ 50 μM, and some significantly inhibited cdc2 at concns. of 50 ≤ μM. Thus, these compds. are useful in the treatment of cancer and hyperproliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections, and inflammatory disorders.
IT 262433-14-7P 262433-27-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)
RN 262433-14-7 CAPLUS
CN Carbamic acid, [5-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 262433-27-2 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(6-amino-3-pyridinyl)-7-cyclopentyl- (CA INDEX NAME)



IT 262430-12-6P 262430-25-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)
RN 262430-12-6 CAPLUS
CN Benzenesulfonamide, N-[5-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-pyridinyl]- (CA INDEX NAME)



RN 262430-25-1 CAPLUS
CN Carbamic acid, [5-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-pyridinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



L8 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2003:202427 CAPLUS
DN 138:221789
TI Preparation of dioxolane and oxathiolane nucleosides as antivirals and inhibitors of RNA-dependent RNA viral polymerase
IN Carroll, Steven S.; MacCoss, Malcolm; Kuo, Lawrence C.; Olsen, David B.; Bhat, Balkrishen; Eldrup, Anne Bettina; Prhavc, Marija; Malik, Leila; Bera, Sanjib
PA Merck & Co., Inc., USA; Isis Pharmaceuticals, Inc.
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003020222	A2	20030313	WO 2002-US28078	20020829
	WO 2003020222	A3	20031127		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002329970	A1	20030318	AU 2002-329970	20020829
PRAI	US 2001-317070P	P	20010904		
	WO 2002-US28078	W	20020829		

OS MARPAT 138:221789
AB The present invention provides 1,3-dioxolane and 1,3-oxathiolane derivs. I, wherein X is O or S(O)n; n is 0-2; R1 is hydrogen, Me, hydroxymethyl, or fluoromethyl; R2 and R3 are each independently hydrogen or alkyl, wherein alkyl is optionally substituted with hydroxy, amino, alkoxy, alkylthio, or one to three halogen atoms; R4 is H, alkylcarbonyl, phosphate; R5 is H, alkyl, alkynyl, halogen, cyano, carboxy, alkyloxycarbonyl, azido, amino, alkylamino, di(alkyl)amino, hydroxy, alkoxy, alkylthio, alkylsulfonyl, aminomethyl; R6 is hydrogen, cyano, nitro, alkyl, NHCONH2, amide, ester, C(=NH)NH2, hydroxy, alkoxy, amino, alkylamino, di(alkyl)amino, halogen, (1,3-oxazol-2-yl), (1,3-thiazol-2-yl), or (imidazol-2-yl); R7 and R8 are each independently hydrogen, hydroxy, halogen, alkoxy, amino, alkylamino, di(alkyl)amino, cycloalkylamino, or di(cycloalkyl)amino; wherein said RNA-dependent RNA viral polymerase is Flaviviridae viral polymerase or Picornaviridae viral polymerase and said RNA-dependent RNA viral replication is Flaviviridae viral replication or Picornaviridae viral replication. These compds. are also inhibitors of RNA-dependent RNA viral replication and are useful in the treatment of RNA-dependent RNA viral infection. The invention also describes pharmaceutical compns. containing such 1,3-dioxolane and 1,3-oxathiolane derivs. alone or in combination with other agents active against RNA-dependent RNA viral infection. Also disclosed are methods of inhibiting RNA-dependent RNA viral polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the compds. of the present invention. Flaviviridae viral polymerase is selected from the group consisting of hepatitis C virus polymerase,

yellow fever virus polymerase, dengue virus polymerase, West Nile virus polymerase, Japanese encephalitis virus polymerase, and bovine viral diarrhea virus (BVDV) polymerase. Thus, cis-2-hydroxymethyl-4-(4-amino-5-carboxy-1H-pyrrolo[2,3-d]pyrimidin-7-yl)-1,3-dioxolane was prepared as antiviral agent and inhibitor of RNA-dependent RNA viral polymerase.

IT 501013-64-5P 501013-65-6P 501013-75-8P
501013-76-9P 501013-89-4P 501013-90-7P
501014-00-2P 501014-01-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of dioxolane and oxathiolane nucleosides as antivirals and inhibitors of RNA-dependent RNA viral polymerase)

RN 501013-64-5 CAPLUS
CN 1,3-Dioxolane-2-methanol, 4-[4-amino-5-(1H-imidazol-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-, (2R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 501013-65-6 CAPLUS
CN 1,3-Dioxolane-2-methanol, 4-[4-amino-5-(2-oxazolyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-, (2R,4R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 501013-75-8 CAPLUS
CN 1,3-Oxathiolane-2-methanol, 5-[4-amino-5-(1H-imidazol-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-, (2R,5S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 501013-76-9 CAPLUS
CN 1,3-Oxathiolane-2-methanol, 5-[4-amino-5-(2-oxazolyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-, (2R,5S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 501013-89-4 CAPLUS
CN 1,3-Dioxolane-2-methanol, 4-[4-amino-5-(1H-imidazol-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 501013-90-7 CAPLUS
CN 1,3-Dioxolane-2-methanol, 4-[4-amino-5-(2-oxazolyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-, (2R,4R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 501014-00-2 CAPLUS
CN 1,3-Oxathiolane-2-methanol, 5-[4-amino-5-(1H-imidazol-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-, (2S,5R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 501014-01-3 CAPLUS
CN 1,3-Oxathiolane-2-methanol, 5-[4-amino-5-(2-oxazolyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-, (2S,5R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2000:784379 CAPLUS
DN 133:350235
TI Preparation of heterocyclic substituted cyclopentane compounds as inhibitors of adenosine kinase
IN Bhagwat, Shripad S.; Cowart, Marlon Daniel
PA Abbott Laboratories, USA
SO U.S., 31 pp., Cont.-in-part of U.S. Ser. No. 472,486, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6143749	A	20001107	US 1996-651882	19960604
	CA 2220006	A1	19961219	CA 1996-2220006	19960606
	WO 9640686	A1	19961219	WO 1996-US9042	19960606
	W: CA, JP, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 873340	A1	19981028	EP 1996-918151	19960606
	EP 873340	B1	20011121		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2000501694	T	20000215	JP 1997-501456	19960606
	AT 209206	T	20011215	AT 1996-918151	19960606
	PT 873340	T	20020531	PT 1996-918151	19960606
	ES 2168479	T3	20020616	ES 1996-918151	19960606
PRAI	US 1995-472486	B2	19950607		
	US 1996-651882	A	19960604		
	WO 1996-US9042	W	19960606		

OS MARPAT 133:350235
AB Heterocyclic substituted cyclopentane compds. I [X = CR7; Y = N, CH; R1 and R2 are each independently hydroxy, alkoxy, or acyloxy or R1 and R2 are both hydroxy protected with an individual hydroxy protecting group or with a single dihydroxy-protecting group or R1 and R2 are absent and there is a double bond between the carbon atoms to which R1 and R2 are attached; R3 = hydrogen, hydroxy, alkoxy; R4 = H, amino, halo, etc.; R5 = hydrogen, lower alkyl, aryl, arylalkyl, heteroaryl, amino, alkylamino, alkoxy, acylamino, arylalkynyl, arylamino, arylmercapto, alkylmercapto, etc.; R6 = lower alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, alkoxycarbonyl, etc.;], useful in inhibiting adenosine kinase, were prepared E.g., N-((1'R,2'S,3'R,4'S)-2',3',4'-triacetoxycyclopentyl)-4-chloropyrrolopyrimidine was prepared
IT 1098232-85-9 1098232-87-1
RL: PRPH (Prophetic)
(Preparation of heterocyclic substituted cyclopentane compounds as inhibitors of adenosine kinase)
RN 1098232-85-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



no -L-(CH2)j-R3 substituent on the hetero ring

RN 1098232-87-1 CAPLUS
CN 1,2-Cyclopentanediol, 3-amino-5-[4-amino-5-(3-pyridinyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl]-, (1R,2S,3R,5S)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 2000:210171 CAPLUS
DN 132:251159
TI Preparation of 4-aminopyrrolopyrimidines as protein kinase inhibitors
IN Calderwood, David; Arnold, Lee D.; Mazdiyasni, Hormoz; Hirst, Gavin; Deng, Bojuan B.
PA BASF Aktiengesellschaft, Germany
SO PCT Int. Appl., 242 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

the IA is filed after Nov 29, 2000

therefore, no 102(e) date

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000017202	A1	20000330	WO 1999-US21536	19990917
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2344262	A1	20000330	CA 1999-2344262	19990917
	AU 9960475	A	20000410	AU 1999-60475	19990917
	AU 752474	B2	20020919		
	EP 1114052	A1	20010711	EP 1999-969414	19990917
	EP 1114052	B1	20051116		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	TR 200101395	T2	20011121	TR 2001-1395	19990917
	BR 9913888	A	20020108	BR 1999-13888	19990917
	HU 2002000355	A2	20020629	HU 2002-355	19990917
	HU 2002000355	A3	20040728		
	JP 2002527359	T	20020827	JP 2000-574111	19990917
	NZ 510587	A	20031128	NZ 1999-510587	19990917
	AT 310001	T	20051215	AT 1999-969414	19990917
	ES 2253930	T3	20060601	ES 1999-969414	19990917
	NO 2001001357	A	20010514	NO 2001-1357	20010316
	BG 105355	A	20011130	BG 2001-105355	20010316
	ZA 2001002201	A	20020315	ZA 2001-2201	20010316
	IN 2001CN00364	A	20050304	IN 2001-CN364	20010316
	HK 1039325	A1	20060224	HK 2002-100226	20020111
PRAI	US 1998-100954P	P	19980918		
	WO 1999-US21536	W	19990917		

OS MARPAT 132:251159
AB 7H-Pyrrolo[2,3-d]pyrimidin-4-amines (I) [wherein A = (un)substituted 6-membered aromatic ring or 5- or 6-membered heteroarom. ring; L = RbN(R)S(O)2, RbN(R)P(O), or RbN(R)P(O)O, where Rb = alkylene group which when taken together with the sulfonamide, phosphinamide or phosphonamide group to which it is bound forms a 5- or 6-membered ring fused to ring A, or L = O, S, N(R), 5-, 6-, or 7-membered (oxa)azaphosphaarom. or (oxa)azaphosphacycloalkyl ring, or a variety of linkers containing functional groups; R = H, acyl, or (un)substituted aliphatic, (hetero)aromatic, or cycloalkyl; R1 = H, 2-Ph-1,3-dioxan-5-yl or (un)substituted (cyclo)alkyl, cycloalkenyl, or phenylalkyl; R2 = H, halo, OH, CN, (un)substituted aliphatic, cycloalkyl, (hetero)aromatic, (hetero)aralkyl, amino, or amido; R3

(un)substituted aliphatic, alkenyl, (hetero)cycloalkyl, or (hetero)aromatic; n = 0-6], and physiol. acceptable salts and metabolites thereof, were prepared For example, II was prepared in a 6-step sequence involving: (1) amine protection of 4-bromo-2-methoxyaniline with di-tert-Bu dicarbonate, (2) 4-addition of diboron pinacol ester, (3) 4-substitution with 4-chloro-7-cyclopentyl-5-iodo-7H-pyrrolo[2,3-d]pyrimidine, (4) deprotection of the amine with F3CCO2H, (5) 4-amination of the pyrrolopyrimidine, and (6) addition of 4-cyanobenzenesulfonyl chloride to the anilino amine. I inhibit serine/threonine and tyrosine kinase activity, affecting immunol., hyperproliferative, and angiogenic processes. All exemplified compds. significantly inhibited either FGFR, PDGFR, KDR, Tie-2, Lck, Fyn, Blk, Lyn, or Src at concns. of ≤ 50 μM, and some significantly inhibited cdc2 at concns. of 50 ≤ μM. Thus, these compds. are useful in the treatment of cancer and hyperproliferative disorders, rheumatoid arthritis, disorders of the immune system, transplant rejections, and inflammatory disorders.

IT 262433-14-7P 262433-27-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)

RN 262433-14-7 CAPLUS
CN Carbamic acid, [5-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-pyridinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 262433-27-2 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(6-amino-3-pyridinyl)-7-cyclopentyl- (CA INDEX NAME)



IT 262430-12-6P 262430-25-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of 7H-pyrrolo[2,3-d]pyrimidin-4-amines as protein kinase inhibitors)
RN 262430-12-6 CAPLUS
CN Benzenesulfonamide, N-[5-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-pyridinyl]- (CA INDEX NAME)



RN 262430-25-1 CAPLUS
CN Carbamic acid, [5-(4-amino-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-2-pyridinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1984:188438 CAPLUS
DN 100:188438
OREF 100:28595a,28598a
TI Modified labeled nucleotides and polynucleotides and methods of utilizing and detecting them
IN Engelhardt, Dean; Rabbani, Elazar; Kline, Stanley; Stavrianopoulos, Jannis G.; Kirtikar, Dollie
PA Enzo Biochem, Inc., USA
SO Eur. Pat. Appl., 140 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 97373	A2	19840104	EP 1983-106112	19830622
	EP 97373	A3	19840606		
	EP 97373	B1	19921007		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	CA 1223831	A1	19870707	CA 1983-430882	19830621
	IL 69051	A	19880229	IL 1983-69051	19830622
	EP 285057	A2	19881005	EP 1988-104961	19830622
	EP 285057	A3	19901031		
	EP 285057	B1	19950301		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	EP 285058	A2	19881005	EP 1988-104962	19830622
	EP 285058	A3	19900926		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	EP 285950	A2	19881012	EP 1988-104964	19830622
	EP 285950	A3	19901107		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	EP 286898	A2	19881019	EP 1988-104963	19830622
	EP 286898	A3	19900808		
	EP 286898	B1	19980429		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	EP 302175	A2	19890208	EP 1988-104965	19830622
	EP 302175	A3	19901031		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 81342	T	19921015	AT 1983-106112	19830622
	EP 618228	A1	19941005	EP 1994-105993	19830622
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	AT 165605	T	19980515	AT 1988-104963	19830622
	DK 8302911	A	19831224	DK 1983-2911	19830623
	NO 8302292	A	19831227	NO 1983-2292	19830623
	AU 8316179	A	19840105	AU 1983-16179	19830623
	AU 585199	B2	19890615		
	JP 59062600	A	19840410	JP 1983-113599	19830623
	JP 11292892	A	19991026	JP 1999-8415	19830623
	DK 8401306	A	19840229	DK 1984-1306	19840229
	DK 8401307	A	19840229	DK 1984-1307	19840229
	AU 8941493	A	19900104	AU 1989-41493	19890915
	US 5241060	A	19930831	US 1990-532704	19900604
	US 5260433	A	19931109	US 1990-567039	19900813
	JP 06234787	A	19940823	JP 1993-177184	19930610
	JP 2760466	B2	19980528		
	US 6992180	B1	20060131	US 1995-479997	19950607

	US 7220854	B1	20070522	US 1995-486066	19950607
	JP 10158294	A	19980616	JP 1997-295889	19971028
	JP 3170235	B2	20010528		
PRAI	US 1982-391440	A	19820623		
	EP 1983-106112	P	19830622		
	EP 1988-104961	A3	19830622		
	DK 1983-2911	A	19830623		
	JP 1993-177184	A3	19830623		
	JP 1997-295889	A3	19830623		
	US 1984-674352	B1	19841121		
	US 1988-140980	B3	19880105		
	US 1990-532461	B1	19900531		
	US 1990-531953	B1	19900601		
	US 1992-960071	B1	19921013		
	US 1993-46004	B1	19930409		

AB Nucleotides, polynucleotides, and DNA were chemical modified or labeled with chemical moieties which were readily detectable. These chemical moieties included carbohydrates and sugars, electron dense substances, magnetic substances, enzymes, coenzymes, hormones, radioactive substances, metals, fluorescent substances, antigens, or antibodies. These chemical modified nucleotides were used for: (1) stimulating or inducing cells to produce lymphokines, cytokinins, and interferon; (2) testing resistance of bacteria to antibiotics; (3) diagnosing genetic disorders, e.g., β-thalassemia; (4) diagnosing tumors; (5) diagnosing bacteria, virus, or fungus infection; and (6) karyotyping chromosomes.

IT 55470-39-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 55470-39-8 CAPLUS

CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-β-D-ribofuranosyl-5-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
AN 1975:422239 CAPLUS
DN 83:22239
OREF 83:3528h,3529a
TI Pyrrolopyrimidine nucleosides. VIII. Synthesis of sangivamycin derivatives possessing exocyclic heterocycles at C5
AU Schram, Karl H.; Townsend, Leroy B.
CS Dep. Biopharm. Sci., Univ. Utah, Salt Lake City, UT, USA
SO Journal of Carbohydrates, Nucleosides, Nucleotides (1974), 1(1), 39-54
CODEN: JCNNAF; ISSN: 0094-0585
DT Journal
LA English
AB The effect on antileukemic activity exerted by the introduction of exocyclic heterocyclic rings at the 5 position of 4-amino-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine (I) was studied. Ring closures on the cyano group of toyocamycin [606-58-6] were effected using various 1,3-dipolar addition reactions to form 5- and 6-membered heterocyclic rings. Condensation of 4-amino-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine-5-carboxamidrazone [22242-91-7] with diketones led to substituted as-triazines while aldehydes furnished certain 1,2,4-triazoles. Preparation of a 1,2,4-oxadiazole derivative [55470-44-5] was achieved using 4-amino-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine-5-carboxamidoxime [22242-89-3]. Ring annulation of 4-amino-7-(β-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine-5-thiocarboxamide [22242-90-6] with phenacyl bromide furnished a thiazole derivative [55470-45-6]. Antileukemia testing data indicated that a 6-membered nonarom. ring is the largest group which can be accommodated at C5 without a complete loss of activity. All of the 5-membered heterocyclic rings showed some activity. Activity was highest when the ring was nonarom. and a 5-membered nonarom. ring was more active than a 6-membered nonarom. ring. None of these derivs. were as active as the compds. with smaller nonannulated groups at position 5.
IT 55470-34-3P 55470-35-4P 55470-36-5P
55470-37-6P 55470-38-7P 55470-39-8P
55470-40-1P 55470-41-2P 55470-44-5P
55470-45-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and neoplasm inhibiting activity of)
RN 55470-34-3 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-β-D-ribofuranosyl-5-(1,2,4-triazin-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 55470-35-4 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(5,6-dimethyl-1,2,4-triazin-3-yl)-7-β-D-ribofuranosyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 55470-36-5 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 5-(5,6-diphenyl-1,2,4-triazin-3-yl)-7-β-D-ribofuranosyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 55470-37-6 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
7-β-D-ribofuranosyl-5-(1H-1,2,4-triazol-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 55470-38-7 CAPLUS
CN 3H-1,2,4-Triazole-3-thione, 5-(4-amino-7-β-D-ribofuranosyl-7H-
pyrrolo[2,3-d]pyrimidin-5-yl)-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 55470-39-8 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
7-β-D-ribofuranosyl-5-(1H-tetrazol-5-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 55470-40-1 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
5-(4,5-dihydro-1H-imidazol-2-yl)-7-β-D-ribofuranosyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 55470-41-2 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
7-β-D-ribofuranosyl-5-(1,4,5,6-tetrahydro-2-pyrimidinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 55470-44-5 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
5-(1,2,4-oxadiazol-3-yl)-7-β-D-ribofuranosyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 55470-45-6 CAPLUS
CN 7H-Pyrrolo[2,3-d]pyrimidin-4-amine,
5-(4-phenyl-2-thiazolyl)-7-β-D-ribofuranosyl- (CA INDEX NAME)

Absolute stereochemistry.



```
=> log y
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                45.62     234.12

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -6.56      -6.56

STN INTERNATIONAL LOGOFF AT 17:09:00 ON 21 APR 2009
```